Orlistat
Efficacy and Safety of ATL-962 in Obese Diabetics
Empros Pharma AB · Phase 2 · Completed · Enrollment 600
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Registry arm not named | Obesity + T2D | n/r | n/r | n/r | n/r |
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Orlistat
Empros Pharma AB · Phase 2 · Completed · Enrollment 600
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Registry arm not named | Obesity + T2D | n/r | n/r | n/r | n/r |